PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Dalacin-T Gel Post Approval Study
Phase 4
Completed
- Conditions
- Acne Vulgaris
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 134
- Registration Number
- NCT00219570
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder Syndrome
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220376
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder Syndrome
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220402
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
Phase 2
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220389
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00219557
- Locations
- 🇺🇸
Southeast Nebraska Cancer Center, Southeast Nebraska Hematology and Oncology Consultants, P.C., Lincoln, Nebraska, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇺🇸East Bay Medical Oncology/Hematology Medical Associates, Inc., Concord, California, United States
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7609
- Registration Number
- NCT00205777
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
Use of 852A in Metastatic Cutaneous Melanoma.
Phase 2
Completed
- Conditions
- MelanomaUnresectable Metatstatic Cutaneous Melanoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-10-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00189332
- Locations
- 🇫🇷
Hôpital Ste Marguerite,Service de Dermatologie, Marseilles, France
🇩🇪Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany
🇩🇪(DKFZ) an der Universitäts-Hautklinik Mannheim, Mannheim, Germany
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT00195260
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00195338
- Locations
- 🇱🇺
Pfizer Investigational Site, Luxembourg, Luxembourg
A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1014
- Registration Number
- NCT00195403
© Copyright 2025. All Rights Reserved by MedPath